Wednesday, December 1, 2021
I pity the fool who thinks the Covid-19 pandemic is drawing to an end.
Thanks to a new variant dubbed Omicron, reality is setting in that Covid is here to stay.
But panic-selling all your stocks whenever a new variant pops up isn’t the right response…
Instead, you should be buying stocks — specifically, the ones that are uniquely positioned to overcome the shortcomings of early vaccines.
And today, I have not one but two such opportunities for you to consider.
But first, a quick primer on the topic at hand…
By now, you’ve probably seen pictures of the Covid-19 virus, like the one below.
What you might not realize is that every vaccine in development or being administered focuses on just one way of fighting the virus.
They target a single spike protein to create an immune response to fight the virus.
But here’s the thing: research has shown that 50% of antibodies associated with fighting off the Covid-19 virus are non-spike ones.
That means that almost every vaccine maker is ignoring up to 99% of the targets that create a successful immune response to clear the virus.
As a result, they’re completely ill-equipped to handle mutations.
Why? Because the majority of mutations are occurring in spike proteins. So if a vaccine is only targeting one of them, and the virus mutates away from that spike protein, the vaccine will no longer work.
Or as Eric Topol, director of the Scripps Research Translational Institute in San Diego notes, “We see an unequivocal drop-off in efficacy [because of mutations].”
Sure enough, on the heels of the discovery of the Omicron variant, the largest vaccine makers are now sprinting to develop new vaccines. They’re being forced to adjust their targets to maintain efficacy.
Newsflash: Once the virus mutates again, they’ll have to adjust their targets again… and again… and again.
Naturally, these adjustments take time, which gives the virus time to spread and mutate more rapidly. In other words, Big Pharma is playing an endless game of catch-up.
But what if we could find smaller companies using approaches that aren’t exposed to the risk of “mutational drift”?
Sure enough, by focusing our attention on companies developing multi-target vaccines, or using approaches showing durability across variants, we can uncover unspoiled Covid-19 investment opportunities.
Like TFF Pharmaceuticals, Inc. (TFFP).
Founded in 2018, this clinical-stage biopharmaceutical company focuses on developing and commercializing innovative inhalable drug products based on its Thin Film Freezing technology platform.
Without going too deeply into the science, here’s what you need to know:
The company’s technology improves the water solubility of drugs, which is a major innovation, as 33% of approved drugs worldwide have poor water solubility.
In other words, a third of all approved drugs are being delivered via a suboptimal method, and in turn, generating suboptimal results.
That means patient outcomes are being negatively impacted because of an inability to effectively administer drugs. But not when TFF’s technology is employed.
It just so happens that one of the company’s many active opportunities involves an inhalable version of AUG-3387, a monoclonal antibody (mAb) Covid-19 therapy being developed in collaboration with Augmenta Bioworks.
Here’s the key: pre-clinical studies (published here) show that AUG-3387 effectively neutralized all major Covid variants of concern.
What’s more, as the company revealed in a press release (emphasis mine):
“[The data] suggests AUG-3387 targets a highly conserved region of the virus, making AUG-3387 likely to remain effective despite the frequent emergence of new variant strains.”
Long story short, AUG-3387 ranks as one of the most promising ways to treat the constantly mutating Covid-19 virus. And it’s about to go into the clinic, which means it could be on the market shortly thereafter, given the urgent global need.
But TFF isn’t the only (or best) Omicron variant stock you should buy today…
My favorite stock is a micro-cap innovator that should be dosing patients with its unique B-cell therapy in a matter of weeks.
In fact, it’s one of my highest-conviction picks in my premium advisory, Micro-Cap Advantage.
And later this week, I’ll be publishing research that reviews all the reasons why.
To make sure you receive this information, contact Lauren, our Customer Care Director. You can reach her toll-free at 1-844-575-7767.
Ask her about a special risk-free trial offer.
Ahead of the tape,